(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 November 2009 (19.11.2009)

PCT

(10) International Publication Number
WO 2009/138788 A1

(51) International Patent Classification:
C07D 239/84 (2006.01) *A61P 7/02* (2006.01)
A61K 31/517 (2006.01)

(21) International Application Number:
PCT/GB2009/050508

(22) International Filing Date:
13 May 2009 (13.05.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0808948.4 16 May 2008 (16.05.2008) GB

(71) Applicant *(for all designated States except US)*: **SHIRE LLC** [US/US]; 9200 Brookfield Court, Florence, Kentucky 41042 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GOLDING, Bernard** [GB/GB]; 42 Dukesfield, Shiremoor, Newcastle upon Tyne, Tyne and Wear NE27 0EZ (GB). **CICALA, Peter** [US/US]; Shire Pharmaceuticals, Inc., 725 Chesterbrook Boulevard, Wayne, Pennsylvania 19087-8301 (US). **FRANKLIN, Richard** [GB/GB]; 3 Rosedene Gardens, Fleet, Hampshire GU51 4NQ (GB). **MACLEOD, Angus** [GB/GB]; BioFocus DPI, Chesterford Research Park, Saffron Walden, Essex CB10 1XL (GB).

(74) Agent: **Harrison Goddard Foote**; Belgrave Hall, Belgrave Street, Leeds, West Yorkshire LS2 8DD (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2009/138788 A1

(54) **Title**: SUBSTITUTED QUINAZOLINES



(I)

(57) **Abstract**: This invention relates to the discovery of prodrugs of substituted analogues of the selective platelet lowering agent anagrelide which have reduced potential for cardiovascular side-effects and which should therefore lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to prodrugs of certain imidazoquinazoline derivatives which have the general formula (I) shown below wherein the substituents have the meanings defined in claim 1 and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting the formation of blood platelets.